Does the media favor ONC or APGE?

In the previous week, Apogee Therapeutics had 4 more articles in the media than BeOne Medicines. MarketBeat recorded 16 mentions for Apogee Therapeutics and 12 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.22 beat Apogee Therapeutics' score of 0.20 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Apogee Therapeutics 4 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer APGE or MRNA?

In the previous week, Moderna had 5 more articles in the media than Apogee Therapeutics. MarketBeat recorded 21 mentions for Moderna and 16 mentions for Apogee Therapeutics. Moderna's average media sentiment score of 0.55 beat Apogee Therapeutics' score of 0.20 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 4 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 8 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BNTX or APGE?

In the previous week, Apogee Therapeutics had 12 more articles in the media than BioNTech. MarketBeat recorded 16 mentions for Apogee Therapeutics and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.37 beat Apogee Therapeutics' score of 0.20 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 4 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ROIV or APGE?

In the previous week, Roivant Sciences had 1 more articles in the media than Apogee Therapeutics. MarketBeat recorded 17 mentions for Roivant Sciences and 16 mentions for Apogee Therapeutics. Roivant Sciences' average media sentiment score of 1.12 beat Apogee Therapeutics' score of 0.20 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 11 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 4 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer APGE or INSM?

In the previous week, Insmed had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 19 mentions for Insmed and 16 mentions for Apogee Therapeutics. Insmed's average media sentiment score of 1.10 beat Apogee Therapeutics' score of 0.20 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 4 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Insmed 13 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Apogee Therapeutics (APGE) Competitors

$132.73 +0.12 (+0.09%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$132.68 -0.05 (-0.04%)

As of 04:05 AM Eastern

Compare

APGE vs. ONC, MRNA, BNTX, ROIV, and INSM

Should you buy Apogee Therapeutics stock or one of its competitors? MarketBeat compares Apogee Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Apogee Therapeutics include BeOne Medicines (ONC), Moderna (MRNA), BioNTech (BNTX), Roivant Sciences (ROIV), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

How does Apogee Therapeutics compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BeOne Medicines has a net margin of 8.94% compared to Apogee Therapeutics' net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Apogee Therapeutics	N/A	-32.64%	-31.25%

BeOne Medicines has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.85	$286.93M	$4.47	63.75
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

In the previous week, Apogee Therapeutics had 4 more articles in the media than BeOne Medicines. MarketBeat recorded 16 mentions for Apogee Therapeutics and 12 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.22 beat Apogee Therapeutics' score of 0.20 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apogee Therapeutics	4 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines presently has a consensus target price of $390.00, suggesting a potential upside of 36.86%. Apogee Therapeutics has a consensus target price of $121.25, suggesting a potential downside of 8.65%. Given BeOne Medicines' stronger consensus rating and higher probable upside, equities research analysts clearly believe BeOne Medicines is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24

Summary

BeOne Medicines beats Apogee Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Apogee Therapeutics compare to Moderna?

Apogee Therapeutics (NASDAQ:APGE) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, Moderna had 5 more articles in the media than Apogee Therapeutics. MarketBeat recorded 21 mentions for Moderna and 16 mentions for Apogee Therapeutics. Moderna's average media sentiment score of 0.55 beat Apogee Therapeutics' score of 0.20 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	4 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	8 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Apogee Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Apogee Therapeutics has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Moderna	-143.55%	-26.64%	-19.32%

Apogee Therapeutics has higher earnings, but lower revenue than Moderna. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Moderna	$1.94B	14.29	-$2.82B	-$8.15	N/A

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Apogee Therapeutics currently has a consensus target price of $121.25, indicating a potential downside of 8.65%. Moderna has a consensus target price of $37.13, indicating a potential downside of 46.98%. Given Apogee Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Apogee Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Summary

Apogee Therapeutics beats Moderna on 9 of the 16 factors compared between the two stocks.

How does Apogee Therapeutics compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

BioNTech has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

15.5% of BioNTech shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Apogee Therapeutics has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Apogee Therapeutics	N/A	-32.64%	-31.25%

BioNTech presently has a consensus target price of $129.56, indicating a potential upside of 39.24%. Apogee Therapeutics has a consensus target price of $121.25, indicating a potential downside of 8.65%. Given BioNTech's stronger consensus rating and higher possible upside, research analysts clearly believe BioNTech is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24

Apogee Therapeutics has lower revenue, but higher earnings than BioNTech. Apogee Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.25	-$1.29B	-$5.88	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

In the previous week, Apogee Therapeutics had 12 more articles in the media than BioNTech. MarketBeat recorded 16 mentions for Apogee Therapeutics and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.37 beat Apogee Therapeutics' score of 0.20 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	4 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BioNTech beats Apogee Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Apogee Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Apogee Therapeutics has lower revenue, but higher earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,081.71	-$299.77M	-$0.60	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

Roivant Sciences has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

Roivant Sciences presently has a consensus price target of $33.59, suggesting a potential downside of 5.08%. Apogee Therapeutics has a consensus price target of $121.25, suggesting a potential downside of 8.65%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Apogee Therapeutics has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Apogee Therapeutics	N/A	-32.64%	-31.25%

In the previous week, Roivant Sciences had 1 more articles in the media than Apogee Therapeutics. MarketBeat recorded 17 mentions for Roivant Sciences and 16 mentions for Apogee Therapeutics. Roivant Sciences' average media sentiment score of 1.12 beat Apogee Therapeutics' score of 0.20 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	11 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	4 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Roivant Sciences beats Apogee Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Apogee Therapeutics compare to Insmed?

Apogee Therapeutics (NASDAQ:APGE) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

In the previous week, Insmed had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 19 mentions for Insmed and 16 mentions for Apogee Therapeutics. Insmed's average media sentiment score of 1.10 beat Apogee Therapeutics' score of 0.20 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	4 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	13 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Apogee Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Insmed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Apogee Therapeutics has higher earnings, but lower revenue than Insmed. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Insmed	$606.42M	38.11	-$1.28B	-$5.75	N/A

Apogee Therapeutics presently has a consensus price target of $121.25, suggesting a potential downside of 8.65%. Insmed has a consensus price target of $211.86, suggesting a potential upside of 98.71%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Apogee Therapeutics has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Apogee Therapeutics' return on equity of -32.64% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Insmed	-144.44%	-130.11%	-51.57%

79.0% of Apogee Therapeutics shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Insmed beats Apogee Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Apogee Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APGE vs. The Competition

Export

Metric	Apogee Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.21B	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-30.65	20.90	27.25	24.87
Price / Sales	N/A	341.80	543.53	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	10.03	8.75	10.93	6.54
Net Income	-$255.84M	$23.81M	$3.57B	$336.70M
7 Day Performance	0.03%	3.60%	2.31%	2.88%
1 Month Performance	67.38%	3.72%	1.39%	0.64%
1 Year Performance	199.89%	68.80%	36.73%	31.34%

Apogee Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APGE Apogee Therapeutics	1.3555 of 5 stars	$132.73 +0.1%	$121.25 -8.6%	+205.6%	$8.21B	N/A	N/A	91
ONC BeOne Medicines	4.7689 of 5 stars	$274.92 +1.1%	$390.00 +41.9%	+17.7%	$30.16B	$5.34B	61.50	12,000	Analyst Upgrade
MRNA Moderna	1.1051 of 5 stars	$62.76 +5.8%	$36.60 -41.7%	+153.8%	$24.90B	$1.94B	N/A	4,700
BNTX BioNTech	4.2637 of 5 stars	$91.40 +1.3%	$129.56 +41.8%	-12.6%	$23.11B	$3.25B	N/A	7,807	Positive News
ROIV Roivant Sciences	2.0279 of 5 stars	$31.33 +0.2%	$33.59 +7.2%	+214.0%	$22.53B	$8.26M	N/A	860	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APGE) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apogee Therapeutics (APGE) Competitors

APGE vs. ONC, MRNA, BNTX, ROIV, and INSM

How does Apogee Therapeutics compare to BeOne Medicines?

Summary

How does Apogee Therapeutics compare to Moderna?

Summary

How does Apogee Therapeutics compare to BioNTech?

Summary

How does Apogee Therapeutics compare to Roivant Sciences?

Summary

How does Apogee Therapeutics compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APGE vs. The Competition

Apogee Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apogee Therapeutics (APGE) Competitors

APGE vs. ONC, MRNA, BNTX, ROIV, and INSM

How does Apogee Therapeutics compare to BeOne Medicines?

Which has more volatility & risk, ONC or APGE?

Do institutionals & insiders hold more shares of ONC or APGE?

Is ONC or APGE more profitable?

Which has preferable earnings and valuation, ONC or APGE?

Does the media favor ONC or APGE?

Do analysts recommend ONC or APGE?

Summary

How does Apogee Therapeutics compare to Moderna?

Does the media prefer APGE or MRNA?

Which has more risk & volatility, APGE or MRNA?

Is APGE or MRNA more profitable?

Which has preferable earnings & valuation, APGE or MRNA?

Do institutionals & insiders have more ownership in APGE or MRNA?

Do analysts recommend APGE or MRNA?

Summary

How does Apogee Therapeutics compare to BioNTech?

Which has more risk and volatility, BNTX or APGE?

Do institutionals and insiders believe in BNTX or APGE?

Is BNTX or APGE more profitable?

Do analysts recommend BNTX or APGE?

Which has better valuation and earnings, BNTX or APGE?

Does the media favor BNTX or APGE?

Summary

How does Apogee Therapeutics compare to Roivant Sciences?

Which has preferable valuation and earnings, ROIV or APGE?

Which has more risk & volatility, ROIV or APGE?

Do analysts recommend ROIV or APGE?

Do institutionals & insiders hold more shares of ROIV or APGE?

Is ROIV or APGE more profitable?

Does the media favor ROIV or APGE?

Summary

How does Apogee Therapeutics compare to Insmed?

Does the media prefer APGE or INSM?

Which has more volatility and risk, APGE or INSM?

Which has preferable earnings and valuation, APGE or INSM?

Do analysts prefer APGE or INSM?

Is APGE or INSM more profitable?

Do insiders and institutionals hold more shares of APGE or INSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APGE vs. The Competition

Apogee Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools